Glonghui April 24 丨 Fosun Pharma (600196)(02196pokergameset.HK) Announcementpokergameset, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(hereinafter referred to as "the Company") The listing registration application for cycloserine capsules (hereinafter referred to as "the new drug") independently developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a holding subsidiary of Shenyang Hongqi Pharmaceutical Co., Ltd.(hereinafter referred to as "the Company") is used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria that are sensitive to the drug and that are not well treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin and ethambutol) was recently approved by the State Food and Drug Administration.

The new drug is a chemical independently developed by the group (i.e. the company and its holding subsidiaries/units, the same below). It is mainly used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria that are sensitive to the drug and that are not well treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin and ethambutol). As of March 2024, the Group's cumulative R & D investment in this new drug at this stage is approximately RMB 11.76 million (unaudited).